PMC:6723065 / 27959-28303 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/6723065","sourcedb":"PMC","sourceid":"6723065","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6723065","text":"During progression of PD, the beneficial effects of early stage therapies may reduce, because of dopaminergic progressive neuronal loss [15], and therefore management of MS becomes more complicated. Disabling manifestations of this advanced state include worsening of balance, falls, increasing compromise of gait, and speech disturbances [11].","tracks":[{"project":"2_test","denotations":[{"id":"31434341-12498954-7278302","span":{"begin":137,"end":139},"obj":"12498954"},{"id":"31434341-6067254-7278303","span":{"begin":340,"end":342},"obj":"6067254"}],"attributes":[{"subj":"31434341-12498954-7278302","pred":"source","obj":"2_test"},{"subj":"31434341-6067254-7278303","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#93eca7","default":true}]}]}}